Revive Therapeutics (FRA:31R) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Revive Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Revive Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was €-0.60 Mil. Revive Therapeutics's Revenue for the three months ended in Dec. 2023 was €0.00 Mil. Therefore, Revive Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Revive Therapeutics's current FCF Yield % is -12.82%.

The historical rank and industry rank for Revive Therapeutics's FCF Margin % or its related term are showing as below:

FRA:31R's FCF Margin % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: -0.68
* Ranked among companies with meaningful FCF Margin % only.

Revive Therapeutics FCF Margin % Historical Data

The historical data trend for Revive Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revive Therapeutics FCF Margin % Chart

Revive Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

Revive Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Revive Therapeutics's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Revive Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revive Therapeutics's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Revive Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Revive Therapeutics's FCF Margin % falls into.

Revive Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Revive Therapeutics's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-4.186	/	0
	=	%

Revive Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-0.604	/	0
	=	%

Revive Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Revive Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Revive Therapeutics (FRA:31R) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Revive Therapeutics Ltd (FRA:31R) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

RVVTF:USA RVV:Canada

Address

82 Richmond Street East, Toronto, ON, CAN, M5C 1P1

Website

https://www.revivethera.com

Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care.

Revive Therapeutics (FRA:31R) Headlines

No Headlines